With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

In other recent news, Trinity Biotech reported a 3% year-on-year revenue growth in its third quarter of 2024, amounting to $15.2 million. Despite a post-tax net loss of $4.8 million, the company ...

Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its continuous glucose monitoring system. Trinity Biotech plc (NASDAQ: TRIB ...

Shares of TRIB opened at $0.76 on Friday. Trinity Biotech has a twelve month low of $0.74 and a twelve month high of $3.55. The stock has a market cap of $13.72 million, a PE ratio of -0.34 and a ...

Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. Trinity Biotech PLC (TRIB) reports a 14% revenue increase with ...

Trinity Biotech PLC (NASDAQ:TRIB), a leading diagnostic substances company with a market capitalization of $13.12 million, has successfully amended and restated its credit and guaranty agreement ...